LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Childhood Kidney Cancer Arises from Altered Normal Tissue

By LabMedica International staff writers
Posted on 16 Dec 2019
Print article
Image: Histopathology of Wilms tumor or nephroblastoma which is a type of kidney cancer that is seen predominantly in children (Photo courtesy of Nephron).
Image: Histopathology of Wilms tumor or nephroblastoma which is a type of kidney cancer that is seen predominantly in children (Photo courtesy of Nephron).
While kidney cancer in children is rare, the most common type is Wilms tumor, which mostly affects children under the age of five. Most cases of Wilms tumor can be cured through surgery to remove the afflicted kidney in combination with chemotherapy and possibly radiotherapy.

In adults, cancers are typically thought to arise through premalignant clonal expansion, but it's been unclear whether the process is similar in pediatric cancers. Scientists have sequenced tumor and normal kidney tissue to find that alterations indicative of disease were present in some normal tissue from patients as well as in tumors, indicating that that these changes affect cells from which Wilms tumors may later arise.

A large team of scientists working with the Wellcome Sanger Institute (Hinxton, UK) sequenced kidney samples from 54 people, including nearly two dozen children with Wilms tumor, the parents of children with Wilms tumor, and others. The team constructed phylogenetic trees of tumor development based on the somatic mutations present. For three children with unilateral Wilms tumor, they sampled their tumors, blood, and histologically normal kidney and uncovered mosaic mutations within these samples. As some of these mosaic mutations were found in both normal and tumor kidney tissue, though not in blood the investigator suspected that these mutations might have undergone clonal expansions within the kidney.

The scientists folded in additional samples from other Wilms tumor cases; they found these clonal expansions within normal kidney tissue in 61% of the 23 cases they examined. But when they examined tissues from people without Wilms, they found that these clonal expansions were not common in normal kidney development. Instead, these expansions within histologically normal tissue were atypical outcomes of renal development that appear to precede development of Wilms tumor. Nearly 60% of these normal kidney tissues with clonal nephrogenesis exhibited hypermethylation of the H19 locus, which typically acts to regulate cell growth and is a known Wilms tumor driver. This hypermethylation was found throughout the clone. This suppression of H19 leads cells to grow more rapidly to create this swathe of pre-malignant cells from which Wilms tumor may then arise.

Sam Behjati, MA, BM, BCh (Oxon), PhD, a consultant pediatric oncologist and senior study author, said, “The discovery of the genetic root of Wilms' tumor signals a shift in our understanding of this particular cancer and childhood cancer more generally. Our findings represent a radical departure from how we think about Wilms' tumors because we never expected to find the root of cancer in normal-looking tissue.”

The authors concluded that phylogenetic analyses of bilateral tumors indicated that clonal expansions can evolve before the divergence of left and right kidney primordia. These findings reveal embryonal precursors from which unilateral and multifocal cancers develop. The study was published on December 6, 2019 in the journal Science.

Related Links:
Wellcome Sanger Institute

Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.